Document is current

Article History

Received: 23 July 2024

Accepted: 7 February 2025

First Online: 21 February 2025

Declarations

:

: All participants consented to participate before beginning the online survey and prior to the interviews. Given the objectives, the intended use of the collected data, and the methodologies employed, this non-interventional research does not fall under any legislation requiring Institutional Review Board (IRB) approval in Austria, Belgium, France, Germany, Italy, the Netherlands, Spain, or the United Kingdom. In the extend applicable to its non-interventional nature, this research was conducted in accordance with the ethical principles of the Declaration of Helsinki. To comply with the general standards required for scientific publications, the survey obtained ethics approval from the French Institutional Review Board, Comité de Protection des Personnes, Ile de France IV, Hôpital Saint-Louis (N°IRB 00003835) under the registration number 2021-A01712-39 and methodological approval by the French Data Privacy Agency, Commission Nationale Informatique & Libertés under the reference number 2222822 v 0.

: Part A, the online questionnaire, only contains anonymous data and consent for publication was not applicable. Participants in Part B, the interviews, provided their consent for publication of pseudonymised data before participation in an interview.

: MS received research grants from Novartis, Trudell pharma, GSK, and the Tel Aviv League for lung diseases; travel grants- Novartis, Actelion, Boeringer Ingelheim, GSK, Rafa. Speaker’s fees- Astra Zeneca, Boeringer Ingelheim, GSK, Insmed, Teva, Novartis, Kamada, Sanofi. Advisory fees (incl. steering committee membership)- GSK, Boeringer Ingelheim, Kamada, Syncrony medical, Zambon, Vertex pharmaceuticals. DSMB Participation- Bonus therapeutics, Israel. RvL and MO are employees of Insmed, the company that funded the survey. CH, RL and AR are employees of admedicum, which received funding from Insmed to conduct the research. NL received consultancy fees from Insmed, GSK, AN2 Therapeutics, speaker’s fees from GSK and Insmed, and a travel grant from Pfizer. All fees were provided to her institution, not to the author personally.